Stocks and Investing
Stocks and Investing
Tue, March 5, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
John Sourbeer Maintained (AKYA) at Strong Buy with Increased Target to $7.5 on, Mar 5th, 2024
John Sourbeer of UBS, Maintained "Akoya Biosciences, Inc." (AKYA) at Strong Buy with Increased Target from $7 to $7.5 on, Mar 5th, 2024.
John has made no other calls on AKYA in the last 4 months.
There are 3 other peers that have a rating on AKYA. Out of the 3 peers that are also analyzing AKYA, 1 agrees with John's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Subbu Nambi of "Guggenheim" Initiated at Hold on, Thursday, December 14th, 2023
These are the ratings of the 2 analyists that currently disagree with John
- David Westenberg of "Piper Sandler" Maintained at Buy with Decreased Target to $8 on, Monday, November 13th, 2023
- Mason Carrico of "Stephens & Co." Maintained at Buy with Decreased Target to $9 on, Monday, November 13th, 2023
Contributing Sources